Example of using IoT wearable and Analytics to address Parkinson's disease

1. December 6-8, 2015 • Dubai, United Arab Emirates
Rick Cnossen, Intel Global Director- Healthcare
Transforming Healthcare with IoT

2. © 2015 Cisco and/or its affiliates. All rights reserved. 2
Intel's Vision
This decade we will create and extend computing technology to
connect and enrich the lives of every person on earth
2

3. © 2015 Cisco and/or its affiliates. All rights reserved. 3
What’s Driving IoT in Healthcare?
Pay for Outcome
Wellness Programs
Reduce Cost of Chronic CareReduce Readmissions
Patient IncentivesClinical Trials

4. Objective
Evaluate consumer perceptions
of technology innovations and
various ways that it is expected
to impact daily life.
Methodology
Penn Schoen Berland conducted
a quantitative poll with over
12,000 interviews, spanning
8 countries in Q3, 2013.
Intel Global
Innovation Survey
4

5. Intel Global
Innovation Survey
5

6. Intel Global
Innovation Survey
6

7. How It All Started?
7
Big data analytics
IOT

8. Parkinson’s Disease
8
OVER AGE
0F 60
1/100 60,000
NEW
1M/US
5M/WORLD
NO CURE,
MEDICATION ONLY HELPS WITH
SYMPTOMSThere is
NO TEST
and no
PROGRESSION
MARKER
PARKINSON’S DISEASE IS CAUSED BY THE DEATH
OF DOPAMINE CELLS.
OF THESE CELLS ARE ALREADY LOST BY THE TIME
MOTOR SYMPTOMS APPEAR.
60 80%TO

9. HOW?
9

10. Please raise your hand, if
you can articulate how
you have felt in the last
12 months in comparison
to the previous year.

11. 11
You can't
Manage
what you can't
Measure

12. The Solution
Wear a watch Start an application
12
1 2

13. Use Cases
MANAGE
THE
DISEASE
USING
DATA
FREE DATA
FOR 1000’S
OF PATIENTS
ACCURATE
REPORT
SINCE LAST
VISIT
MEASURE
MEDICATION
EFFECT
RESEARCHER
PHARMACEUTICAL
CLINICIAN
BIG DATA CLOUDANALYTICS
INSIGHT / VALUE
13

14. THE APPLICATION
14

15. 10
Medication
reporting &
reminders
Questions
per cohort
Symptoms
tracking
OTHER
Gamification
Contribution
score
Medication /
Protocol
Adherence Metronome
Gait
Sleep
Tremor
Activity
Level
Controlled
Tests
Services: Data collection & Patient engagement
OBJECTIVE
MEASURES
PATIENT
REPORTED

16. Medication
Reminders
Medication /
Symptoms tracking
Questions per trail

17. Activity Level
• Continuously describe the intensity of the
patient’s activity throughout the day
alongside the medication reporting.
• Motivates the patients to be more active
(known to be important for PD patients)
• Personalized measure based on their average
activity (avoid frustration)
• Based on intensity measurement from the
accelerometer
• Filters out tremor
17

18. Tremor
• Tremor is detectable using signal processing
techniques
• Algorithm is based on tremor frequencies of
3.5Hz-11Hz according to literature review
• Tremor episodes are detected based on the
frequency, duration and intensity of the
periodic movement
18

19. Night Time Movement Tracking
• Most PD patients suffer from some sleep disorder
and some have PD symptoms during the night
• Provide patients with movement analysis during
the night
• Report on Low ,Medium and High activity periods
during the night will allow the patients to better
plan their sleep and wake up times as well as
their medications
19

20. Structured Tests

21. BIG-DATA Analytics
21

22. Wearable Cloud Analytics Framework
Cloud Infrastructure
Data Platform
Analytics Platform
Downstream
Export
Analysis &
Mining tools
22
• Self reported – Questions, Feedbacks, Medication reporting
• Structured tests – Gait, Alternating hand movement
• 24/7 analyzed data– Activity, Tremor, Sleep

23. Analytics
CLINICAL TRIALS
Create and Validate
Algorithm & Measures
POPULATION STUDY
23
Generate insights
Using Big data analytics

24. SERVICE LAYER
BATCH LAYER
STREAM ANALYICS LAYER
INGESTION LAYER
STORAGE LAYER
USER INTERFACE LAYER
Mosquitto
24
CLOUD COMPUTING SERVICES
Domain Specific General Purpose

25. Challenges To Address
NO
OBJECTIVE
MEASURE
3-6 MONTHS
BETWEEN
PHYSICIAN
VISITS
CHANGES ARE
SLOW
AND HARD TO
DETECT
AVERAGE
TRIAL SIZE
< 100
PATIENTS
VERY
SMALL
number of
patients
contribute
to research
COST OF
TRIALS
are in the
scales of
$M
25

26. © 2015 Cisco and/or its affiliates. All rights reserved. 26
Intel Healthcare Wearable Video Link

27. © 2015 Cisco and/or its affiliates. All rights reserved. 27
Intel Across Healthcare: Learn More
www.intel.com/healthcare
Rick.a.cnossen@intel.com
Policy and Standards
Mobile Healthcare Care Coordination Secure Cloud Devices and Imaging
Performance Big Data Aging
2

28. © 2015 Cisco and/or its affiliates. All rights reserved. 28
Notice and Disclaimers
 Notice: This document contains information on products in the design phase of development. The information here is subject to change without notice. Do not
finalize a design with this information. Contact your local Intel sales office or your distributor to obtain the latest specification before placing your product order.
 INFORMATION IN THIS DOCUMENT IS PROVIDED IN CONNECTION WITH INTEL® PRODUCTS. EXCEPT AS PROVIDED IN INTEL'S TERMS AND
CONDITIONS OF SALE FOR SUCH PRODUCTS, INTEL ASSUMES NO LIABILITY WHATSOEVER, AND INTEL DISCLAIMS ANY EXPRESS OR IMPLIED
WARRANTY RELATING TO SALE AND/OR USE OF INTEL PRODUCTS, INCLUDING LIABILITY OR WARRANTIES RELATING TO FITNESS FOR A
PARTICULAR PURPOSE, MERCHANTABILITY, OR INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER INTELLECTUAL PROPERTY RIGHT. Intel
products are not intended for use in medical, life saving, or life sustaining applications. Intel may make changes to specifications, product descriptions, and plans
at any time, without notice.
 All products, dates, and figures are preliminary for planning purposes and are subject to change without notice.
 Designers must not rely on the absence or characteristics of any features or instructions marked "reserved" or "undefined.“ Intel reserves these for future
definition and shall have no responsibility whatsoever for conflicts or incompatibilities arising from future changes to them.
 Performance tests and ratings are measured using specific computer systems and/or components and reflect the approximate performance of Intel products as
measured by those tests. Any difference in system hardware or software design or configuration may affect actual performance.
 The Intel products discussed herein may contain design defects or errors known as errata which may cause the product to deviate from published specifications.
Current characterized errata are available on request.
 Knights Corner, Knights Ferry, Aubrey Isle and other code names featured are used internally within Intel to identify products that are in development and not yet
publicly announced for release. Customers, licensees and other third parties are not authorized by Intel to use code names in advertising, promotion or
marketing of any product or services and any such use of Intel's internal code names is at the sole risk of the user.
 opies of documents which have an order number and are referenced in this document, or other Intel literature, may be obtained by calling 1-800-548-4725, or by
visiting Intel's website at http://www.intel.com.
 Intel®, Itanium®, Xeon®, Pentium®, and the Intel logo are trademarks or registered trademarks of Intel Corporation or its subsidiaries in the United States and
other countries.
 Copyright © 2011-14015, Intel Corporation. All rights reserved.
 *Other names and brands may be claimed as the property of others.
2